Form 4: Amgen SVP & CCO Nancy A. Grygiel Reports Changes in Beneficial Ownership

Nancy A. Grygiel, SVP & CCO of Amgen Inc., reports changes in beneficial ownership of Amgen stock due to the disposition of shares to cover tax obligations and acquisitions through the company's 401(k) plan.

Summary

• On July 31, 2024, Nancy A. Grygiel, SVP & CCO of Amgen Inc., filed a Form 4 with the SEC.
• The filing reports the disposition of 1,565 shares of common stock at a price of $333.28 per share to satisfy tax obligations.
• The filing also reports the acquisition of 100.6967 shares through the company's 401(k) plan.
• Following the reported transactions, Grygiel directly owns 8,771 shares of Amgen common stock and indirectly owns shares through the 401(k) plan.
• The directly owned shares include Restricted Stock Units (RSUs) that will vest in future years.
• The shares also include Dividend Equivalents (DEs) granted pursuant to the Company's Equity Plan and subject to a qualifying dividend reinvestment plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by an executive. The acquisition of shares through the 401(k) plan is a slightly positive signal.

Positives

• Acquisition of shares through the 401(k) plan indicates confidence in the company's future.

Future Outlook

The document does not contain specific forward-looking statements, but it does detail the vesting schedule for RSUs, indicating future equity compensation.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in company stock. This filing is typical for executives at publicly traded companies like Amgen.

Comparison to Industry Standards

• Executive compensation packages at large pharmaceutical companies like Amgen often include a mix of salary, stock options, and restricted stock units.
• Vesting schedules for RSUs are common, typically spanning several years to incentivize long-term performance.
• Companies like Johnson & Johnson, Pfizer, and Merck also have similar equity incentive plans for their executives.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• The filing provides transparency to shareholders regarding insider transactions.

Key Dates